Stockreport

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Clearmind Medicine Inc.  (CMND) 
PDF For the first time, patients with alcohol use disorder will receive the company's unique and proprietary psychedelic - MEAI Vancouver, Canada, Feb. 23, 2024 (GLOBE N [Read more]